Condition: Pulmonary Hypertension · Interstitial Lung Disease · Sponsor: Insmed Incorporated
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
This description comes directly from the study's public registry record.
Insmed Medical Information · 18444467633 · medicalinformation@insmed.com
Always discuss trial participation with your own doctor first.
| USA010 | Los Angeles, California, United States | Not Yet Recruiting |
| USA001 | Santa Barbara, California, United States | Not Yet Recruiting |
| USA006 | Naples, Florida, United States | Recruiting |
| USA026 | St. Petersburg, Florida, United States | Not Yet Recruiting |
| USA002 | Kansas City, Kansas, United States | Not Yet Recruiting |
| USA003 | Bend, Oregon, United States | Recruiting |
| USA013 | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| USA008 | Richmond, Virginia, United States | Not Yet Recruiting |
| ARG002 | CiudadAutonoma de Buenos Aires, Buenos Aires, Argentina | Not Yet Recruiting |
| ARG003 | Río Cuarto, Córdoba Province, Argentina | Not Yet Recruiting |
| ARG008 | San Miguel de Tucumán, Tucumán Province, Argentina | Not Yet Recruiting |
| ARG004 | Córdoba, Argentina | Not Yet Recruiting |
+ 97 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07179380